GS
TTNP

Gagnon Securities’s Titan Pharmaceuticals TTNP Stock Holding History

Gagnon Securities’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-10
Closed -$61K – 95
2017
Q3 		$61K Hold
10
– – 0.02% 91
2017
Q2 		$67 Buy
+10
New +$93K 0.02% 83
2016
Q3 		– Sell
-17
Closed -$340K – 99
2016
Q2 		$340K Buy
+17
New +$362K 0.16% 67

Other funds holding TTNP

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WPA
Winning Points Advisors Boca Raton, Florida $74.8M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SRAM
Stone Ridge Asset Management New York $475M AUM
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Gagnon Securities's TTNP Position: Q4 2017 in Review

Gagnon Securities sold out of Titan Pharmaceuticals (TTNP) in Q4 2017, closing a stake of 10 shares — an estimated $61K sold.

Gagnon Securities first reported a position in TTNP in Q2 2016 and held it in 3 quarters. The position peaked at $340K in Q2 2016. 21 funds tracked by Wall St. Rank hold TTNP as of Q4 2017.

  • Gagnon Securities reported no remaining Titan Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Gagnon Securities sold 10 Titan Pharmaceuticals shares in Q4 2017, an estimated $61K.
  • Gagnon Securities first reported a position in Titan Pharmaceuticals in Q2 2016 and held it in 3 quarters.
  • Gagnon Securities's Titan Pharmaceuticals position peaked at $340K in Q2 2016.
  • 21 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q4 2017.

Based on Gagnon Securities's 13F filing for Q4 2017, filed 13 Feb 2018.